Research programme: arrhythmia therapeutics - AstraZeneca

Drug Profile

Research programme: arrhythmia therapeutics - AstraZeneca

Alternative Names: AZD 3118

Latest Information Update: 17 Dec 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Arrhythmias

Most Recent Events

  • 17 Dec 2007 Discontinued - Preclinical for Arrhythmias (unspecified route)
  • 31 Jul 2007 Preclinical trials in Arrhythmias (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top